Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial...

Area of Science:

• Oncology
• Molecular Pathology
• Translational Research

Background:

• Breast cancer is a complex, heterogeneous disease requiring precise patient management.
• Current predictive biomarkers (estrogen receptor, progesterone receptor, HER2) are limited for guiding novel targeted therapies.
• Assessing dynamic tumor response and the role of molecular alterations is challenging with conventional pathology.

Purpose of the Study:

• To highlight the need for advanced predictive markers beyond current standards in breast cancer.
• To emphasize the integration of molecular pathology, imaging, and early therapeutic response for optimizing treatment selection.
• To explore the potential of assessing adaptive tumor response as a key resistance mechanism in the neoadjuvant setting.

Main Methods:

• Review of current breast cancer biomarkers and targeted therapy challenges.
• Discussion on integrating multi-modal data (molecular pathology, imaging, early response) for treatment decisions.
• Focus on neoadjuvant trials for validating novel predictive markers.

Main Results:

• Conventional pathology has limitations in assessing dynamic treatment response and the significance of molecular alterations.
• Early assessment of tumor biological response can provide evidence of drug activity and inform therapy adjustments.
• Adaptive tumor response is a critical resistance mechanism identifiable in the neoadjuvant setting.

Conclusions:

• There is a critical need for novel predictive markers in breast cancer management.
• Integrating diverse data sources offers a promising approach to personalize therapy and overcome resistance.
• Neoadjuvant trials are crucial for validating new biomarkers and understanding drug sensitivity and resistance mechanisms.